Evidence map›Paper›PMID 28828352›Full record

ArticleProstate international2017

Report of the Second Asian Prostate Cancer (A-CaP) Study Meeting.

Choung-Soo Kim, Ji Youl Lee, Byung Ha Chung, Wun-Jae Kim, Ng Chi Fai, Lukman Hakim, Rainy Umbas, Teng Aik Ong, Jasmine Lim, Jason L Letran and 19 more

Open access · goldAbstract read
In one paragraph

Article in Prostate international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 20 institutions in 11 countries.

Choung-Soo KimDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Ji Youl LeeDepartment of Urology, St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
Byung Ha ChungDepartment of Urology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
Wun-Jae KimDepartment of Urology, Chungbuk National Medical University Hospital, Cheongju, South Korea.
Ng Chi FaiSH Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China.
Lukman HakimDepartment of Urology, Airlangga University/Dr. Soetomo General Hospital of Surabaya, Surabaya, East Java, Indonesia.
Rainy UmbasDepartment of Urology, Dr. Cipto Mangunkusumo Hospital/Faculty of Medicine, University of Indonesia, Depok City, West Java, Indonesia.
Teng Aik OngDepartment of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Jasmine LimDepartment of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Jason L LetranDepartment of Urology, Cardinal Santos Medical Center, Manila, Philippines.
Edmund ChiongDepartment of Urology, University Surgical Cluster, National University Health System (NUHS), Singapore.
Tong-Lin WuDepartment of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Bannakij LojanapiwatDepartment of Surgery, Faculty of Medicine, Chiang Mai University, Thailand.
Levent TürkeriDepartment of Urology, Acıbadem University Medical Faculty, Istanbul, Turkey.
Declan G MurphyDivision of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Robert A GardinerUniversity of Queensland Centre for Clinical Research at Royal Brisbane & Women's Hospital, Brisbane, QLD, Australia.
Kim MorettiSchool of Population Health, University of South Australia, Adelaide, SA, Australia.
Matthew CooperbergDepartment of Urology, School of Medicine, University of California San Francisco, San Francisco, CA, USA.
Peter CarrollDepartment of Urology, UCSF-Helen Diller Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Seong Ki MunOpen Source Electronic Health Record Alliance, Arlington, VA, USA.
Shiro HinotsuCenter for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
Yoshihiko HiraoOsaka Gyoumeikan Hospital, Osaka, Japan.
Seiichiro OzonoDepartment of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Shigeo HorieDepartment of Urology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Mizuki OnozawaDepartment of Urology, Tokyo Kita Medical Center, Tokyo, Japan.
Yasuhide KitagawaDepartment of Integrative Cancer Therapy and Urology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.
Tadaichi KitamuraFaculty of Medicine, University of Tokyo, Tokyo, Japan.
Mikio NamikiGraduate School of Medical Science, Kanazawa University, Japan.
Hideyuki AkazaDepartment of Strategic Investigation on Comprehensive Cancer Network, Graduate School of Interdisciplinary Information Studies, University of Tokyo, Tokyo, Japan.
The University of Tokyo · JPUniversity of Malaya · MYAcıbadem University · TRAirlangga University · IDCatholic University of Korea · KRChiang Mai University · THChinese University of Hong Kong · HKChungbuk National University Hospital · KRGangnam Severance Hospital · KRHamamatsu University School of Medicine · JPJuntendo University · JPKanazawa University · JPKaohsiung Veterans General Hospital · TWNational University Health System · SGOkayama University Hospital · JPOsaka Ekisaikai Hospital · JPProstate Cancer Foundation of Australia · AURoyal Brisbane and Women's Hospital · AUTokyo-Kita Medical Center · JPUCSF Helen Diller Family Comprehensive Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Asian Prostate Cancer (A-CaP) Study is an Asia-wide initiative that has been developed over the course of 2 years. The study was launched in December 2015 in Tokyo, Japan, and the participating countries and regions engaged in preparations for the study during the course of 2016, including patient registration and creation of databases for the purpose of the study. The Second A-CaP Meeting was held on September 8, 2016 in Seoul, Korea, with the participation of members and collaborators from 12 countries and regions. Under the study, each participating country or region will begin registration of newly diagnosed prostate cancer patients and conduct prognostic investigations. From the data gathered, common research themes will be identified, such as comparisons among Asian countries of background factors in newly diagnosed prostate cancer patients. This is the first Asia-wide study of prostate cancer and has developed from single country research efforts in this field, including in Japan and Korea. At the Second Meeting, participating countries and regions discussed the status of preparations and discussed various issues that are being faced. These issues include technical challenges in creating databases, promoting participation in each country or region, clarifying issues relating to data input, addressing institutional issues such as institutional review board requirements, and the need for dedicated data managers. The meeting was positioned as an opportunity to share information and address outstanding issues prior to the initiation of the study. In addition to A-CaP-specific discussions, a series of special lectures was also delivered as a means of providing international perspectives on the latest developments in prostate cancer and the use of databases and registration studies around the world.

Indexed as

AsiaDatabaseProspective studyProstate cancer

Identifiers

PMID28828352
PMCPMC5551923
OpenAlexW2597875844

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.